CJC-1295 (Mod GRF 1-29) Side Effects

Reported CJC-1295 (Mod GRF 1-29) side effects

Expected / benign Injection-site reaction — mild redness, itching, small bump; 24-48 hour resolution Facial flushing / warmth 15-30 min post-injection (histamine release from GHRH action); typically diminishes after week 1-2 Mild nausea in first week at higher doses Transient hunger increase (less than with MK-677 or ghrelin agonists) Dose-dependent Water retention / mild peripheral edema — common in first 2-4 weeks, usually resolves Tingling or numbness in hands / carpal tunnel symptoms — dose-related; if persistent, reduce dose Morning lethargy or grogginess — from sub-optimal GH pulse timing; adjust to pre-bed dosing Joint stiffness — particularly in knees and fingers; dose-responsive Elevated fasting glucose — GH is counter-regulatory to insulin; modest at physiologic doses Uncommon Headache — usually resolves with dose reduction or improved hydration Dizziness or orthostatic hypotension — rare Dream vividness — common with pre-bed dosing Injection-site lipodystrophy — with repeated same-site injection; rotate sites Serious (dose- and duration-dependent) Insulin resistance / impaired glucose tolerance — chronic supraphysiologic GH elevation; rare at proper MOD-GRF 1-29 dosing but more common with DAC variant or MK-677 Acromegaly-like features — not reported at physiologic doses; theoretical at very high chronic dosing Potential malignancy risk — see IGF-1 cancer meta-analysis (Renehan et al., 2004). Elevated IGF-1 is epidemiologically associated with increased prostate, colorectal, and premenopausal breast cancer risk Carpal tunnel syndrome — dose-responsive, typically reversible with dose reduction Absolute contraindications Active malignancy (any type) — GH/IGF-1 signaling may promote tumor growth History of cancer within 5 years — insufficient data to stratify risk Diabetic retinopathy — IGF-1 promotes retinal neovascularization Pregnancy and lactation — no safety data Children with open growth plates — unintended growth acceleration Relative contraindications Type 2 diabetes with poor control (HbA1c >8) — glucose worsening risk Severe hypothyroidism — suboptimal GH axis function; optimize thyroid first Intracranial pathology / elevated ICP — theoretical concern Active autoimmune disease — no direct evidence of harm, but insufficient data Drug interactions Glucocorticoids — suppress GHRH response; minimize if possible High-dose SSRIs / antipsychotics — may blunt GH response Insulin / insulin secretagogues — GH raises glucose; monitor Lab monitoring IGF-1 baseline and 8-12 weeks after starting Fasting glucose and HbA1c quarterly for first year, then annually Age-appropriate cancer screening per USPSTF guidelines (no different from non-users)

When to continue, reduce, or stop CJC-1295 (Mod GRF 1-29)

CJC-1295 (Mod GRF 1-29) contraindications

Absolute contraindications Active malignancy of any type — GH/IGF-1 axis stimulation is theoretically pro-tumorigenic; substantive epidemiologic signal for prostate, colorectal, and premenopausal breast cancer (Renehan et al., 2004) Diabetic retinopathy (active or history) — IGF-1 promotes retinal neovascularization Pregnancy and lactation — no safety data, GH axis alterations during pregnancy have unknown consequences Children with open growth plates — unintended longitudinal growth Critical illness requiring ICU care — exogenous GH increased mortality in critically ill patients ([Takala et al., 1999, NEJM]) Relative contraindications (clinician-guided) History of cancer within 5 years — individualize risk/benefit with oncology Type 2 diabetes with poor control (HbA1c >8) — GH worsens insulin resistance Severe hypothyroidism — suboptimal GH response; optimize thyroid first Intracranial pathology / elevated ICP — theoretical concern with GH Obstructive sleep apnea — GH may exacerbate upper-airway soft tissue Drug interactions Glucocorticoids (prednisone, dexamethasone) — blunt GHRH response; minimize if possible Somatostatin analogs (octreotide, lanreotide) — direct GH suppression; incompatible use Insulin and insulin secretagogues — GH is counter-regulatory; monitor glucose Oral estrogens (high-dose) — blunt hepatic IGF-1 response Chemotherapy agents — avoid concurrent use during active chemo Surgery and procedure considerations Hold for 1-2 weeks before elective major surgery (conservative) Disclose use to all clinicians, particularly oncology, ophthalmology, endocrinology Not a concern for routine procedures (dental, dermatologic) Disclosure obligations All clinicians, especially oncology, ophthalmology, endocrinology Insurance and life-insurance applications (material in some jurisdictions) Anti-doping: GH-releasing peptides are WADA-prohibited at all times — not appropriate for competitive athletes subject to testing

Why vendor quality drives CJC-1295 (Mod GRF 1-29) side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

CJC-1295 (Mod GRF 1-29) side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .